vs
Side-by-side financial comparison of Fluent, Inc. (FLNT) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $61.8M, roughly 1.4× Fluent, Inc.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs -5.5%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -3.2%).
THG Fluently, formerly Language Connect, is a translation and language localisation service provided by THG Ingenuity. It provides a range of language services, including translation, interpreting, localisation, voice-overs, transcription, and multilingual search engine optimization.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
FLNT vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $61.8M | $86.8M |
| Net Profit | $-4.1M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | 0.3% | -84.7% |
| Net Margin | -6.7% | — |
| Revenue YoY | -5.5% | 17.7% |
| Net Profit YoY | -20.1% | — |
| EPS (diluted) | $-0.09 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $61.8M | $86.8M | ||
| Q3 25 | $47.0M | $67.5M | ||
| Q2 25 | $44.7M | $60.0M | ||
| Q1 25 | $55.2M | $49.3M | ||
| Q4 24 | $65.4M | $73.7M | ||
| Q3 24 | $64.5M | $58.6M | ||
| Q2 24 | $58.7M | $31.1M | ||
| Q1 24 | $66.0M | $715.0K |
| Q4 25 | $-4.1M | — | ||
| Q3 25 | $-7.6M | $-91.3M | ||
| Q2 25 | $-7.2M | $-111.7M | ||
| Q1 25 | $-8.3M | $-116.2M | ||
| Q4 24 | $-3.4M | — | ||
| Q3 24 | $-7.9M | $-83.5M | ||
| Q2 24 | $-11.6M | $-97.1M | ||
| Q1 24 | $-6.3M | $-113.0M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | — |
| Q4 25 | 0.3% | -84.7% | ||
| Q3 25 | -13.4% | -140.7% | ||
| Q2 25 | -15.9% | -189.8% | ||
| Q1 25 | -12.8% | -245.8% | ||
| Q4 24 | -8.3% | -117.5% | ||
| Q3 24 | -6.0% | -152.1% | ||
| Q2 24 | -17.7% | -327.6% | ||
| Q1 24 | -6.0% | -16464.6% |
| Q4 25 | -6.7% | — | ||
| Q3 25 | -16.1% | -135.3% | ||
| Q2 25 | -16.2% | -186.2% | ||
| Q1 25 | -15.0% | -235.5% | ||
| Q4 24 | -5.2% | — | ||
| Q3 24 | -12.3% | -142.7% | ||
| Q2 24 | -19.8% | -312.2% | ||
| Q1 24 | -9.5% | -15800.8% |
| Q4 25 | $-0.09 | — | ||
| Q3 25 | $-0.27 | — | ||
| Q2 25 | $-0.30 | $-0.33 | ||
| Q1 25 | $-0.39 | $-0.36 | ||
| Q4 24 | $-0.12 | $-0.24 | ||
| Q3 24 | $-0.48 | $-0.28 | ||
| Q2 24 | $-0.75 | $-0.34 | ||
| Q1 24 | $-0.45 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $12.9M | $297.0M |
| Total DebtLower is stronger | $34.6M | — |
| Stockholders' EquityBook value | $18.2M | $698.6M |
| Total Assets | $89.1M | $913.2M |
| Debt / EquityLower = less leverage | 1.90× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $12.9M | $297.0M | ||
| Q3 25 | $9.2M | $300.8M | ||
| Q2 25 | $4.9M | $301.2M | ||
| Q1 25 | $4.8M | $359.7M | ||
| Q4 24 | $9.4M | $323.8M | ||
| Q3 24 | $6.6M | $397.5M | ||
| Q2 24 | $5.0M | $412.5M | ||
| Q1 24 | $11.7M | $356.2M |
| Q4 25 | $34.6M | — | ||
| Q3 25 | $26.0M | — | ||
| Q2 25 | $23.2M | — | ||
| Q1 25 | $25.6M | — | ||
| Q4 24 | $35.6M | — | ||
| Q3 24 | $37.9M | — | ||
| Q2 24 | $33.3M | — | ||
| Q1 24 | $31.0M | — |
| Q4 25 | $18.2M | $698.6M | ||
| Q3 25 | $21.6M | $702.3M | ||
| Q2 25 | $19.1M | $698.5M | ||
| Q1 25 | $22.0M | $767.9M | ||
| Q4 24 | $25.0M | $710.4M | ||
| Q3 24 | $20.0M | $773.5M | ||
| Q2 24 | $27.5M | $768.5M | ||
| Q1 24 | $28.7M | $680.0M |
| Q4 25 | $89.1M | $913.2M | ||
| Q3 25 | $76.1M | $904.9M | ||
| Q2 25 | $74.5M | $907.4M | ||
| Q1 25 | $77.5M | $966.7M | ||
| Q4 24 | $93.6M | $910.4M | ||
| Q3 24 | $77.5M | $991.1M | ||
| Q2 24 | $98.5M | $964.3M | ||
| Q1 24 | $103.6M | $869.8M |
| Q4 25 | 1.90× | — | ||
| Q3 25 | 1.21× | — | ||
| Q2 25 | 1.21× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.43× | — | ||
| Q3 24 | 1.90× | — | ||
| Q2 24 | 1.21× | — | ||
| Q1 24 | 1.08× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.8M | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.8M | $-52.6M | ||
| Q3 25 | $-7.3M | $-78.7M | ||
| Q2 25 | $935.0K | $-67.4M | ||
| Q1 25 | $2.1M | $-103.7M | ||
| Q4 24 | $-2.1M | $-73.3M | ||
| Q3 24 | $1.2M | $-59.0M | ||
| Q2 24 | $-13.1M | $-98.4M | ||
| Q1 24 | $-132.0K | $-122.3M |
| Q4 25 | — | $-61.9M | ||
| Q3 25 | $-7.3M | $-89.5M | ||
| Q2 25 | — | $-74.9M | ||
| Q1 25 | — | $-109.9M | ||
| Q4 24 | — | $-77.5M | ||
| Q3 24 | $1.2M | $-61.3M | ||
| Q2 24 | — | $-98.9M | ||
| Q1 24 | — | $-126.5M |
| Q4 25 | — | -71.3% | ||
| Q3 25 | -15.6% | -132.7% | ||
| Q2 25 | — | -124.9% | ||
| Q1 25 | — | -222.8% | ||
| Q4 24 | — | -105.1% | ||
| Q3 24 | 1.9% | -104.6% | ||
| Q2 24 | — | -317.9% | ||
| Q1 24 | — | -17685.3% |
| Q4 25 | — | 10.7% | ||
| Q3 25 | 0.0% | 16.1% | ||
| Q2 25 | — | 12.4% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | 0.0% | 3.9% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 583.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FLNT
| Commerce Media Solutions | $34.7M | 56% |
| Owned And Operated | $21.3M | 34% |
| Call Solutions | $3.8M | 6% |
| Ad Parlor | $2.0M | 3% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
